Appendix 1- PRISMA-P 2015 Checklist

This checklist has been adapted for use with protocol submissions to *Systematic Reviews* from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 2015 4:1

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
ADMINISTRATIVE INFORMATION					
Title					
Identification	1a	Identify the report as a protocol of a systematic review	☑		2
Update	1b	If the protocol is for an update of a previous systematic review, identify as such			NA
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract	☑		28
Authors					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author			NA
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	☑		206-212
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments			NA
Support					
Sources	5a	Indicate sources of financial or other support for the review	☑		214-215
Sponsor	5b	Provide name for the review funder and/or sponsor	☑		214-215
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	☑		25-26
INTRODUCTION					
Rationale	6	Describe the rationale for the review in the context of what is already known	☑		42-75
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	☑		76-82 152-169

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
METHODS					
Eligibility criteria	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	☑		144-166
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	☑		90-106
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	☑		Supplemental File 3
STUDY RECORDS					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	☑		125-128
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	☑		129-143
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	☑		149-166
Data items	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	☑		153-161
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	☑		153-161
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	☑		186-195
DATA					
Synthesis	15a	Describe criteria under which study data will be quantitatively synthesized	☑		175-177
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I^2, Kendall's tau)	☑		178-185
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)	☑		169-171
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	☑		197-199

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	☑		18-19
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	☑		196-199

Appendix 2- PRISMA 2009 Flow Diagram



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). *P*referred *R*eporting *I*tems for *S*ystematic Reviews and *M*eta-*A*nalyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.

Appendix3

Table 1 **Search strategy for PubMed**

Quary	Search syntax Related terms/synonyms
#1	(Disease AND Alzheimer) OR “Alzheimer Sclerosis” OR (Sclerosis AND Alzheimer) OR “Alzheimer Syndrome” OR (Syndrome AND Alzheimer) OR “Alzheimer Dementia” OR AD OR (Dementia AND Alzheimer) OR Alzheimer-Type Dementia OR ATD OR Dementia AND Alzheimer-Type OR “Primary Senile Degenerative Dementia” OR (Dementia AND Senile) OR “Senile Dementia” OR (Dementia AND Alzheimer Type) OR “Alzheimer Type Dementia” OR (Senile Dementia AND Alzheimer Type) OR “Alzheimer Type Senile Dementia” OR (Dementia AND Primary Senile Degenerative) OR “Alzheimer's Disease” OR (Disease AND Alzheimer) OR “Acute Confusional Senile Dementia” OR (Senile Dementia AND Acute Confusional) OR (Dementia AND Presenile) OR “Presenile Dementia” OR (Alzheimer Disease AND Late Onset) OR (Alzheimer Disease AND Late Onset) OR (Alzheimer's Disease AND Focal Onset) OR “Focal
#2	(“Toll Like Receptor” OR Toll-Like Receptor OR Receptor AND Toll-Like OR (Receptor AND Toll Like) OR TLR)
#3	#1 AND #2